OptiBiotix Health PLC SlimBiome® distribution agreement for Germany (3997X)
December 19 2019 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 3997X
OptiBiotix Health PLC
19 December 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
SlimBiome(R) distribution agreement for Germany
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high
cholesterol, diabetes and skincare, announces it has entered
into an exclusive agreement with Draco Ingredients GmbH ("Draco")
to distribute OptiBiotix's SlimBiome(R) proprietary weight
management technology in Germany. Market exclusivity is linked to
minimum order quantities in order to maximise the financial return
for both parties.
Draco Ingredients (www.draco-ingredients.de) is a German food
ingredient company established in 2001 focusing on the distribution
of mainly dairy based ingredients to a broad spectrum of customers
active in segments such as dairy, sports and medical nutrition.
This agreement is another step in extending the geographical
reach and sales of SlimBiome(R). This is consistent with our
strategy of increasing the number of geographies and applications
SlimBiome(R) is used in as an ingredient. This builds revenue
potential and brand recognition and reduces commercial risk.
Andre Wittke, General Manager of Draco Ingredients, commented:
"We are delighted to have the opportunity of partnering with
Optibiotix and look forward to building a presence for SlimBiome(R)
in Germany by leveraging on the strengths of both organisations. We
see SlimBiome's unique value proposition (patented solution backed
by clinical and consumer studies and supported by EFSA-approved
claims) as being a key driver of the sale of this functional
ingredient to German customers in the near future."
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics
division, commented: "We are pleased to announce this agreement
with Draco Ingredients to service the German market. The timing of
this agreement fits particularly well with our recent focus on
creating the building-blocks necessary to accelerate and expand our
reach to customers globally. This deal builds on the work done in
2019 to qualify multiple manufacturers of SlimBiome(R) in Europe
and around the world (e.g Zeon: India, Agropur: USA) to de-risk our
supply-chain in the case of a hard Brexit and give us access to one
of Europe's largest economies."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than 20 international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCCKFDNFBDDOBD
(END) Dow Jones Newswires
December 19, 2019 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024